MOLECULAR EVENTS CONTRIBUTING TO THE IMMUNE-MEDIATED BONE MARROW FAILURE IN IDIOPATHIC APLASTIC ANEMIA

EHA Library, Zuzana Lenertova, 420867

SPLICING ALTERATIONS CAUSED BY U2AF1MT-S34 MODIFY THE TRANSCRIPTOME OF POT1 IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS

EHA Library, Alejandro Ferrer, 420868

ZMAT3 PREVENTS HEMATOPOIETIC STEM CELL EXHAUSTION AND CONTRIBUTES TO CELL TRANSFORMATION BY MODULATING SPHINGOLIPID METABOLISM IN FANCONI ANEMIA DISEASE.

EHA Library, Maeva Loock, 420869

METABOLOMICS AND OXIDATIVE DAMAGE IN DIAMOND-BLACKFAN ANEMIA

EHA Library, Ondrej Jahoda, 420870

LONG-READ HLA SEQUENCING UNCOVERS SPECIFIC RISK ALLELES AND CLINICAL ASSOCIATIONS IN APLASTIC ANEMIA

EHA Library, Sunisa Kongkiatkamon, 420871

SPECTRUM OF GENETIC VARIANTS IN AN ARGENTINE PEDIATRIC COHORT WITH SUSPECTED INHERITED BONE MARROW FAILURE SYNDROMES

EHA Library, Agustina Albero, 420872

MUC4 GENE MUTATION PROMOTE COMPLEMENT DEPOSITION AND INCREASE THE RISK OF THROMBOTIC EVENTS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Rong Fu, 420873

EXPRESSION AND MECHANISM OF ACTION OF ASH1L IN NK CELL OF SEVERE APLASTIC ANAEMIA

EHA Library, Mengran Gao, 420874

GENETIC VARIANTS AND INBORN ERRORS OF IMMUNITY IN BONE MARROW FAILURE: NOVEL POTENTIAL DRUG TARGETS FOR PRECISION MEDICINE

EHA Library, Vanessa Desantis, 420875

EFFICACY AND SAFETY OF INTENSIVE PEGCETACOPLAN DOSING FOR THE TREATMENT OF ACUTE HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Morag Griffin, 420876

A NOVEL AUTOSOMAL RECESSIVE TELOMERE BIOLOGY DISORDER CAUSED BY BIALLELIC VARIANTS IN POLA2

EHA Library, Bianca Tesi, 420877

LATE ONSET AND LONG LASTING NEUTROPENIA  IN CHILDREN AND CHRONIC IDIOPATHIC NEUTROPENIA IN ADULTS: DESCRIPTION OF CLINICAL/ IMMUNOLOGICAL PHENOTYPE AND PRELIMINARY WES RESULTS.

EHA Library, Francesca Fioredda, 420878

CLINICAL CHARACTERISTICS AND PROGNOSIS OF SHWACHMAN-DIAMOND SYNDROME PATIENTS WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA  IN CHINA

EHA Library, Yang Wan, 420879

LONG-TERM OUTCOMES OF PEGCETACOPLAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND BASELINE HEMOGLOBIN LEVELS GREATER THAN 10 GRAMS PER DECILITER

EHA Library, Jens Panse, 420880

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES.

EHA Library, Celso Arrais-Rodrigues, 420881

MUTATIONAL LANDSCAPE IN PATIENTS WITH SEVERE APLASTIC ANEMIA IN TAIWAN AND THE CLINICAL SIGNIFICANCE

EHA Library, Kuojui Sun, 420882

CHARACTERIZATION OF CLINICALLY SIGNIFICANT BREAKTHROUGH HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN

EHA Library, Régis Peffault de Latour, 420883

LONGITUDINAL ASSESSMENT OF CLONAL HEMATOPOIESIS DYNAMICS IN CHRONIC IDIOPATHIC NEUTROPENIA (CIN)

EHA Library, Grigorios Tsaknakis, 420884

CLINICAL HETEROGENEITY AND OUTCOME OF PURE RED CELL APLASIA (PRCA): A MULTICENTER INTERNATIONAL STUDY

EHA Library, Francesco Versino, 420885

EFFECTS OF ORAL IPTACOPAN MONOTHERAPY, INCLUDING INCREASED PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RED BLOOD CELL CLONE SIZE, ARE MAINTAINED IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS: FINAL APPOINT-PNH DATA

EHA Library, Antonio Maria Risitano, 420886

PURE RED CELL APLASIA ASSOCIATED WITH THYMIC TUMOURS: A NATIONWIDE COHORT

EHA Library, Mylène Hemmer, 420887

EPIDEMIOLOGY AND REAL-WORLD TREATMENT MANAGEMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN FRANCE

EHA Library, Régis Peffault de Latour, 420888

BREAKTHROUGH HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH COMPLEMENT INHIBITORS: A MULTICENTER INTERNATIONAL STUDY

EHA Library, Bruno Fattizzo, 420890

PREDICTIVE FACTORS FOR THE RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IST-REFRACTORY APLASTIC ANEMIA: DATA FROM TWO CLINICAL TRIALS

EHA Library, Jun-Ho Jang, 420891

RESULTS FROM THE OPEN-LABEL EXTENSION PERIOD OF A PHASE 2 TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN COMBINATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA

EHA Library, Rodrigo Pavani, 420892

EFFECTS OF ORAL IPTACOPAN MONOTHERAPY, INCLUDING INCREASED PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RED BLOOD CELL CLONE SIZE, ARE SUSTAINED IN ANTI-C5-TREATED PATIENTS WITH ANEMIA: FINAL APPLY-PNH DATA

EHA Library, Régis Peffault de Latour, 420893

TREATMENT PATTERNS AND OUTCOMES OF PATIENTS (PTS) WITH ACQUIRED APLASTIC ANEMIA (AA) IN THE UNITED STATES (US): RESULTS FROM A LARGE AND UNIQUE NATIONAL CLAIMS DATABASE

EHA Library, Jessica M. Stempel, 420894

INFLUENTIAL CLINICAL FACTORS ON TELOMERE LENGTH IN PEDIATRIC APLASTIC ANEMIA

EHA Library, Zixi Yin, 420895

ACCESS TO EXPENSIVE DRUGS IN EU COUNTRIES FOR VERY RARE HEMATOLOGICAL BLOOD DISORDERS: THE EXAMPLE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. A SURVEY BY ERN-EUROBLOODNET

EHA Library, Mariangela Pellegrini, 420896

REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH ECULIZUMAB OR RAVULIZUMAB IN THE US - A RETROSPECTIVE CLAIMS DATABASE ANALYSIS

EHA Library, Srinivas Tantravahi, 420897

CLINICAL PHARMACOLOGY OF OMS906, A POTENT INHIBITOR OF MASP-3 AND THE ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION

EHA Library, William Pullman, 420898

EFFICACY AND SAFETY OF POZELIMAB PLUS CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA WHO ARE NAÏVE TO COMPLEMENT INHIBITION

EHA Library, Morag Griffin, 420899

CLINICAL FEATURES AND OUTCOMES IN LARGE GRANULAR LYMPHOCYTE LEUKEMIAÂ ASSOCIATED PURE RED CELL APLASIA WITH STAT3 MUTATION

EHA Library, Guangsheng He, 420900

PHARMACOKINETIC CHARACTERIZATION AND EXPOSURE-RESPONSE RELATIONSHIP OF CROVALIMAB IN THE COMMODORE 1, 2, AND 3 AND COMPOSER TRIALS OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

EHA Library, Rong Fu, 420901

THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE POST-MARKETING SETTING

EHA Library, Jens Panse, 420902

PHASE III COMMODORE 1 AND COMMODORE 2 TRIALS: TREATMENT SATISFACTION AND PREFERENCE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH CROVALIMAB AND ECULIZUMAB OR RAVULIZUMAB

EHA Library, Austin Kulasekararaj, 420903

ELTROMBOPAG PROMOTES THE ENGRAFTMENT OF BONE MARROW FAILURE SYNDROME WITH ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Meng Zhou, 420904

IMPROVEMENT IN IRON OVERLOAD WITH PEGCETACOPLAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PREVIOUSLY TREATED WITH ECULIZUMAB

EHA Library, David Kuter, 420905

ADVANCING INSIGHTS INTO MONOCLONAL ANTIBODY MECHANISMS: A NOVEL EX VIVO ASSAY USING WHOLE BONE MARROW ENVIRONMENT TO INVESTIGATE THE EFFICACY OF DARATUMUMAB IN MULTIPLE MYELOMA.

EHA Library, Jenifer Sanchez, 420906

NONO IS REQUIRED FOR MULTIPLE MYELOMA CELL LINES GROWTH THROUGH STABILISATION OF LNCRNA NEAT1 AND PARASPECKLE INTEGRITY

EHA Library, Elisa Taiana, 420907

BLOCKING LACTATE METABOLISM TO ENHANCE CAR-T THERAPY EFFECT ON MULTIPLE MYELOMA PATIENTS

EHA Library, Zhaoyun Liu, 420908

IRF2 REGULATES SPECIFIC SIGNALING PATHWAYS THAT PARTICIPATE IN THE DEVELOPMENT AND PATHOGENESIS OF MULTIPLE MYELOMA

EHA Library, Nahia Gomez-Echarte, 420909

INFLAMMATORY BONE MARROW MICROENVIRONMENT IMPAIRS RESPONSES TO DARATUMUMAB AND LENALIDOMIDE IN MULTIPLE MYELOMA. A CORRELATIVE STUDY OF THE IFM2017-03 TRIAL.

EHA Library, Silvia Gaggero, 420910

IBERDOMIDE IS IMMUNE STIMULATORY AND INDUCES DEEP ANTI-MYELOMA ACTIVITY ACROSS DOSES IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH TNE NDMM FROM THE CC-220-MM-001 STUDY

EHA Library, Michael Amatangelo, 420911

NON-CODING RNAS REGULATE NOVEL SIGNALING PATHWAYS IN AL AMYLOIDOSIS THAT ARE TARGETABLE BY FDA APPROVED DRUGS

EHA Library, Tal Zvida-Bloch, 420912

FUNCTIONAL DISSECTION AND CLINICAL RELEVANCE  OF THE SINGLE CELL TRANSCRIPTOMIC LANDSCAPE OF GENOTYPICALLY-IDENTIFIED POLYCLONAL PLASMACELLS IN MULTIPLE MYELOMA MICROENVIRONMENT

EHA Library, matteo claudio da via', 420913

EXPRESSION PATTERN OF P53 POST-TRANSLATIONAL MODIFICATIONS AND ITS CLINICAL IMPACT IN HOMOGENOUSLY TREATED MULTIPLE MYELOMA PATIENTS.

EHA Library, Elizabeta A. Rojas, 420914

ALTERATIONS IN CHROMATIN ACCESSIBILITY OF PLASMA CELLS ALLOW NUCLEAR RESPIRATORY FACTOR 1 (NRF1) TO PROMOTE THE DEVELOPMENT AND PROGRESSION OF MULTIPLE MYELOMA.

EHA Library, Giacomo Corleone, 420915

CD4+ CYTOTOXIC T LYMPHOCYTES CONTRIBUTE TO ANTITUMOR IMMUNITY IN MULTIPLE MYELOMA

EHA Library, Hyunsoo Cho, 420916

IMPACT OF PRIOR ANTIBIOTIC EXPOSURE BEFORE INITIATING BISPECIFIC MONOCLONAL ANTIBODY THERAPY IN MULTIPLE MYELOMA

EHA Library, Roberto Garcia-Vicente, 420917

IMPLICATION OF GLYCOLYTIC AND MITOCHONDRIAL METABOLISM IN MULTIPLE MYELOMA RESPONSE TO ANTI-CD38 DARATUMUMAB TREATMENT

EHA Library, Alizée Steer, 420918

DECIPHERING MULTIPLE MYELOMA COMPLEXITY: EXPLORING TUMOR MICROENVIRONMENT DYNAMICS THROUGH MULTI-OMICS INTEGRATION FOR PERSONALIZED THERAPEUTIC INSIGHTS

EHA Library, Elina Alaterre, 420919

HIGH-RESOLUTION SINGLE-CELL RNA SEQUENCING (SCRNA-SEQ) DEFINES DISTINCT NEUTROPHIL GENE SIGNATURES WITHIN FOCAL LESIONS LINKED TO MULTIPLE MYELOMA PROGRESSION FREE SIGNATURE

EHA Library, Philip Mccarthy, 420920

EXPLOITING APOBEC3B-INDUCED VULNERABILITIES FOR RISK-ADAPTED TREATMENT IN MM PATIENTS WITH DEL(17P)

EHA Library, Afsaneh Panahi, 420921

GENETIC DISRUPTION OF BLIMP-1 REMODELS THE TRANSCRIPTOME OF ARI0002H, AN ACADEMIC BCMA-TARGETING CAR-T CELL, TOWARDS A MORE FAVORABLE DIFFERENTIATION PROFILE AND IMPROVED ANTI-TUMOR EFFICACY

EHA Library, Anthony Battram, 420922

CHARACTERIZATION OF BONE MARROW NICHE AND IMMUNOPHENOTYPING IN A MULTIPLE MYELOMA MOUSE MODEL DRIVEN BY COMBINED EXPRESSION OF ACTIVE RANK AND TCL1

EHA Library, Lisa Pfeuffer, 420923

MULTI-OMIC ANALYSIS OF MULTIPLE MYELOMA BY T(11;14) STATUS

EHA Library, Andrew Spencer, 420924

VALIDATION OF PROTOTYPE BIOMARKERS TO IDENTIFY RISK FACTORS OF INFLAMMATORY ADVERSE EVENTS FOLLOWING IDECABTAGENE VICLEUCEL INFUSION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN KARMMA-3

EHA Library, Salomon Manier, 420925

INCREASED WEE1 EXPRESSION CORRELATES WITH POOR SURVIVAL IN MULTIPLE MYELOMA INDEPENDENT OF STANDARD PROGNOSTIC FACTORS

EHA Library, Anish Simhal, 420926

CLINICAL BIOMARKERS ASSOCIATED WITH PROGRESSION FREE SURVIVAL TO CILTACABTAGENE AUTOLEUCEL IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM CARTIFAN-1 STUDY

EHA Library, Jian‑Qing Mi, 420927

UNRAVELLING THE ROLE OF THE NON-IMMUNE BONE MARROW MICROENVIRONMENT IN THE PROGRESSION FROM MGUS TO SMOULDERING AND MULTIPLE MYELOMA

EHA Library, Miguel Cócera Fernández, 420928

GENETIC CHARACTERIZATION OF T(11;14) POSITIVE NEWLY DIAGNOSED MULTIPLE MYELOMA AND MANTLE CELL LYMPHOMA PATIENTS

EHA Library, Jana Wobst, 420929

ALTERATIONS IN EXPRESSION OF GENES CONTROLLING CELL SURFACE SIALYLATION IMPACT PROGNOSIS OF PATIENTS TREATED WITH CURRENT ANTI-MYELOMA THERAPIES

EHA Library, Michael O'Dwyer, 420930

CYCLOPHOSPHAMIDE-POMALIDOMIDE COMBINATION ALTERS THE TUMOUR CELL SECRETOME AND ENHANCES THE ANTI-MYELOMA ACTIVITY OF ELOTUZUMAB THROUGH NK MEDIATED CYTOTOXICITY

EHA Library, Michael O'Dwyer, 420931

OPTICAL GENOME MAPPING RESULTS IN 96 CASES OF MULTIPLE MYELOMA, A NEW OVERVIEW OF THE PLASMA CELL GENOME.

EHA Library, Isabel Granada, 420932

TRANSCRIPTOMIC ANALYSIS OF METABOLISM-ASSOCIATED GENES AS BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS FOR MULTIPLE MYELOMA

EHA Library, Naroa Barrena, 420933

EXOSOME-DERIVED CIRCCOG5 PLAYS A ROLE IN REGULATING RANKL EXPRESSION IN MULTIPLE MYELOMA CELLS BY TARGETING MIR-625-3P

EHA Library, xing cui, 420934

JAK2 AS A POTENTIAL THERAPEUTIC TARGET TO ERADICATE CD34+ MYELOMA-INITIATING CELLS THAT PERSIST AS A MAJOR FRACTION OF MRD

EHA Library, Ko Fujimoto, 420935

ULTRA-SENSITIVE ASSESSMENT OF CFDNA FOR MINIMALLY INVASIVE DETECTION AND CHARACTERIZATION OF MEASURABLE RESIDUAL DISEASE IN MULTIPLE MYELOMA

EHA Library, Natalia Buenache Cuenda, 420936

DISTINCT IMMUNOPHENOTYPE AND GENE EXPRESSION PROFILES OF T CELLS IN PERIPHERAL BLOOD VERSUS BONE MARROW OF PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Glykeria Gkoliou, 420937

BUD23-MEDIATED M7G MODIFICATION PROMOTES MULTIPLE MYELOMA IMMUNE EVASION BY REGULATING IGF2BP1/PD-L1 AXIS

EHA Library, Xing Cui, 420938

EPIGENETIC LIQUID BIOPSY FOR THE DIFFERENTIATION OF BENIGN AND MALIGNANT FORMS OF PLASMA CELL DISORDERS.

EHA Library, Ilana Fox-Fisher, 420939

ASSOCIATION OF PATIENT FACTORS AND PHARMACODYNAMIC BIOMARKERS WITH PROGRESSION-FREE SURVIVAL AFTER IDECABTAGENE VICLEUCEL IN PATIENTS FROM KARMMA-3

EHA Library, Bertrand Arnulf, 420940

UNDERSTANDING THE ROLE OF CAR-NEGATIVE CELLS IN THE EFFICACY AND SAFETY OF CAR-T THERAPIES

EHA Library, Belén Sierro Martínez, 420941

BET INHIBITORS DOWNREGULATE THE EXPRESSION OF THE ESSENTIAL LNCRNA SMILO IN MULTIPLE MYELOMA THROUGH REGULATION OF THE TRANSCRIPTION FACTOR FLI1

EHA Library, Nahia Gomez-Echarte, 420942

CD200 IMMUNE CHECKPOINT EXPRESSION IS ASSOCIATED WITH TREATMENT RESISTANCE AND INFERIOR OUTCOME IN MM PATIENTS TREATED BY ANTI-CD38 MOAB

EHA Library, Charles Herbaux, 420943

WHOLE GENOME SEQUENCING REVEALS SPATIAL HETEROGENEITY OF EXTRAMEDULLARY DISEASE AT DIAGNOSIS AND RELAPSE IN MULTIPLE MYELOMA PATIENTS

EHA Library, sahin sarihan, 420944

LYMPHOCYTOSIS AFTER BCMA CAR-T AS A MARKER OF CAR-T EXPANSION, RESPONSE, AND PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA.

EHA Library, Mark Bustoros, 420945

SOLUBLE BCMA IN LACRIMAL FLUID AS A MEDIATOR OF KERATOPATHY IN MULTIPLE MYELOMA

EHA Library, Umair Munawar, 420946

MULTIPLE MYELOMA INDUCES STRESS-MEDIATED MITOPHAGY, AND IMPAIRS MITOCHONDRIAL FITNESS AND IMMUNE FUNCTION IN NK CELLS

EHA Library, Katia Beider, 420947

B-CELL SUBCLONES CHARACTERIZATION REVEALS THE EVOLUTION OF MYD88 MUTATED IGM MONOCLONAL GAMMOPATHIES

EHA Library, David Moreno, 420948

THE M6A REGULATORY GENES, WITH THE SPECIAL IMPLICATION OF VIRMA, PLAY AN ESSENTIAL ROLE IN MULTIPLE MYELOMA

EHA Library, Estibaliz Urizar-Compains, 420949

MEK1/2 INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS INDUCES IRF1-MEDIATED INTERFERON/PD-L1 SIGNALING AXES IN THE BONE MARROW IMMUNE MICROENVIRONMENT

EHA Library, Chaitanya Acharya, 420950

SINGLE CELL MULTI-OMIC CLONAL TRACKING IN MYELOMA IDENTIFIES SMM CLONES THAT PROGRESS TO MM AND LOW FREQUENCY MM CLONES WITH RESISTANCE FEATURES ENABLING MORE PRECISE APPLICATION OF TARGETED THERAPIES

EHA Library, Todd Druley, 420951

KANSL2 IS AN ACTIONABLE ONCOGENIC DRIVER IN MULTIPLE MYELOMA

EHA Library, Kaiting Jiang, 420952

LIPID-MEDIATED MODULATION OF DNA DAMAGE SIGNALING AS A THERAPEUTIC AND PROGNOSTIC APPROACH AGAINST MULTIPLE MYELOMA

EHA Library, Elvira Garcia de Paco, 420953

BELANTAMAB MAFODOTIN EXHIBITS NO EVIDENCE OF IMMUNE CELL IMPAIRMENT: POTENTIAL IMPLICATIONS FOR SEQUENCING THERAPIES IN MULTIPLE MYELOMA

EHA Library, Michał Mielnik, 420954

NEUTROPHIL-TO-PLATELET RATIO IDENTIFIES MGUS PATIENTS AT HIGH-RISK OF PROGRESSION: A RETROSPECTIVE SINGLE-CENTER STUDY

EHA Library, ALESSANDRA ROMANO, 420955

THE DEVELOPMENTAL STAGE OF MULTIPLE MYELOMA DISCLOSES THE STEMNESS OF LILRB4+ MYELOMA CELLS

EHA Library, Zhen Cai, 420956

BONE MARROW MYELOID PRECURSORS PREDICT TUMOR EVOLUTION AND RESPONSE TO ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA PATIENTS

EHA Library, Cirino Botta, 420957

COMPLEMENT C3A PROMOTES THE FORMATION OF OSTEOCLAST BY INHIBITING SIRT1 TO ACTIVATE THE PI3K/PDK1/SGK3 PATHWAY IN PATIENTS WITH MULTIPLE MYELOMA.

EHA Library, Rong Fu, 420958

CHARACTERISING THE UNMET MEDICAL NEED IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE: INSIGHTS FROM THE PREAMBLE REGISTRY

EHA Library, Claudio Cerchione, 420959

REAL-WORLD TREATMENT TRENDS AND TRIPLE CLASS EXPOSED STATUS IN JAPANESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A RETROSPECTIVE CLAIMS DATABASE STUDY

EHA Library, linghua Xu, 420960

A PATIENT-REPORTED QUESTIONNAIRE MAY ELIMINATE THE NEED FOR AN OPHTHALMIC EXAM BEFORE BELANTAMAB MAFODOTIN DOSING IN NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Evangelos Terpos, 420961

SONROTOCLAX PLUS DEXAMETHASONE IS TOLERABLE AND DEMONSTRATES ANTIMYELOMA ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA HARBORING T(11;14)

EHA Library, Binod Dhakal, 420962

IBERDOMIDE COMBINED WITH LOW-DOSE CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IBERCD): FIRST RESULTS OF THE PHASE 2 ICON STUDY

EHA Library, Charlotte L.B.M. Korst, 420963

AN INDIRECT COMPARISON OF ELRANATAMAB’S PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FROM MAGNETISMM-3 VERSUS COUNTRY-SPECIFIC TREATMENT REGIMENS FROM REAL-WORLD DATA SOURCES

EHA Library, Luciano J. Costa, 420964

REAL-WORLD SCHEDULE DE-ESCALATION OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Saad Z. Usmani, 420966

MEZIGDOMIDE (MEZI), TAZEMETOSTAT (TAZ), AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM THE CA057-003 TRIAL

EHA Library, Luciano J. Costa, 420967

CORRELATIVE BIOMARKER ANALYSES FOR OPTIMAL THERAPEUTIC DOSE DETERMINATION OF ABBV-383, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Katja Weisel, 420968